• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Thrombosomes (Lyophilized Platelets) Appear Safe in Phase 1 Trial

October 24, 2019

 

Data from a phase 1, open-label, multi-center safety trial of lyophilized platelets were recently presented at the 2019 AABB Annual Meeting in San Antonio, Texas. Thrombosomes® (lyophilized platelets) are prepared from a pool of apheresis-derived human platelet units, pathogen-reduced with heat sterilization, and freeze-dried in the presence of trehalose (a naturally-derived simple sugar) and other small molecules which stabilize their structure until reconstruction. In order to test the safety of thrombosomes, three cohorts of eight mildly bleeding thrombocytopenic patients (WHO grades 1-2) were given escalating doses of thrombosomes—from half to two-fold the lowest effective dose (as determined in animal studies). Although 19/24 patients experienced some form of a treatment-emergent adverse event during the study, only one of these events were found to be related to thrombosomes. Additionally, no immediate treatment-related adverse events were observed. Thrombosomes have several potential advantages compared to room-temperature stored platelets: they are stable at room temperature up to 24-36 months, rehydrate quickly, and could be stockpiled or shipped to areas with limited platelet availability. Although thrombosome infusion may appear to be safe and feasible, larger studies are needed, and the homeostatic effects of thrombosomes must be examined further.

 

Reference:

Cancelas Perez JA, Ohanian M, Davenport R, Pullarkat V, et al. Abstract PL2-MN4-32: A phase 1, open-label, multicenter, dose escalation safety trial of lyophilized platelets in bleeding thrombocytopenic patients. Presented at AABB Annual Meeting; 2019 Oct 19-22; San Antonio, TX.

Filed Under

  • News
  • Platelet Transfusion

Recommended

  • Anemia Treatment Bundle Improves Hemoglobin Recovery after Critical Illness

  • AABB and the CDC Outline Guidelines for Laboratory Testing of Patients with Suspected Ebola

  • Coagulopathy in Patients with COVID-19—Interim Guidance from the International Society on Thrombosis and Haemostasis

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

  • Multifaceted Threats to the Blood Supply from Climate Change

  • Distinct Roles for Differently Aged Platelets

  • Anemia Treatment Bundle Improves Hemoglobin Recovery after Critical Illness

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley